drugset / Trial / NCT02661126
Pharmacokinetics of MK-3682B in Participants With Moderate to Severe Renal Insufficiency (MK-3682B-030)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to compare the plasma pharmacokinetics (PK) of single doses of MK-3682B, a fixed dose combination (FDC) tablet containing uprifosbuvir (MK-3682) + grazoprevir (MK-5172) + ruzasvir (MK-8408) in participants with moderate (Part 1) and severe (Part 2) renal insufficiency (RI) to plasma PK in healthy participants.
Timeline
- Start
- 2016-01-19
- Primary completion
- 2016-08-26
- Completion
- 2016-08-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GRAZOPREVIR ANHYDROUS | Small molecule | 50 mg | Oral |
| Subject | Ruzasvir | Other / unclassified | 30 mg | Oral |
| Subject | Uprifosbuvir | Other / unclassified | 225 mg | Oral |